S2 Episode 2: Addressing Common Toxicities for Breast Cancer HER2-Targeted Therapies
Drs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to improve the patient experience. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Polyhydramnios and Oligohydramnios https://emedicine.medscape.com/article/975821-overview Management of Diarrhea in Patients With HER2-Positive Breast Cancer Treated With Neratinib: A Case Series and Summary of The Literature https://pubmed.ncbi.nlm.nih.gov/34800263/ Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/37163123/ The Comparative Efficacy and Risk of Harms of the Intravenous and Subcutaneous Formulations of Trastuzumab in Patients With HER2-Positive Breast Cancer: A Rapid Review https://pubmed.ncbi.nlm.nih.gov/31829250/ Overview of Antibody-Drug Conjugates Nonclinical and Clinical Toxicities and Related Contributing Factors https://pubmed.ncbi.nlm.nih.gov/40491603/ Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations https://pubmed.ncbi.nlm.nih.gov/37554126/ Oral Mucositis Associated With Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment https://pubmed.ncbi.nlm.nih.gov/40712557/ Incidence of Antibody-Drug Conjugate-Related Hepatotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39703774/ T-DM1-Induced Thrombocytopenia in Breast Cancer Patients: New Perspectives https://pubmed.ncbi.nlm.nih.gov/32570117/ Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36454580/ Lung Toxicity Induced by Anti-HER2 Antibody-Drug Conjugates for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38295890/
--------
24:42
--------
24:42
S2 Episode 1: Cardiac Toxicity and HER2-Targeted Therapy: Who's at Risk?
Drs Kathy Miller and Bonnie Ky discuss cardiovascular concerns with HER2-targeted therapies and how to work with cardiology colleagues for the best treatment outcomes. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study https://pubmed.ncbi.nlm.nih.gov/25548585/ MUGA Scan https://www.ncbi.nlm.nih.gov/books/NBK564365/ Myocardial Strain Imaging: Theory, Current Practice, and the Future https://pubmed.ncbi.nlm.nih.gov/39269417/ Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial https://pubmed.ncbi.nlm.nih.gov/36858723/ Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance https://pubmed.ncbi.nlm.nih.gov/40246379/ Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/40537192/ Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology https://pubmed.ncbi.nlm.nih.gov/36213359/ Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity https://pubmed.ncbi.nlm.nih.gov/36612307/ Prospective Evaluation of the Cardiac Safety of HER2-Targeted Therapies in Patients With HER2-Positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study https://pubmed.ncbi.nlm.nih.gov/30852761/ Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial https://pubmed.ncbi.nlm.nih.gov/34396157/
--------
22:54
--------
22:54
S1 Episode 6: New Classification of HER2–Ultra-Low Breast Cancer: What Do We Need to Know?
Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2–ultra-low breast cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001338. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Prevalence of "HER2 Ultra-Low" Among Patients With Advanced Breast Cancer With Historical IHC0 Status https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13156 Targeting HER2-Positive Breast Cancer: Advances and Future Directions https://pubmed.ncbi.nlm.nih.gov/36344672/ Are There More HER2 FISH in the Sea? An Institution's Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients With HER2 Negative Immunohistochemistry https://pubmed.ncbi.nlm.nih.gov/37936021/ Trastuzumab Deruxtecan (T-DXd) vs Physician's Choice of Chemotherapy (TPC) in Patients (Pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (MBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06) https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA1000 The American Society of Clinical Oncology-College of American Pathologists Guideline Update for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37303241/ Prognostic Relevance of the HER2 Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients Screened for Participation in the DETECT Study Program https://pubmed.ncbi.nlm.nih.gov/34839105/ Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update https://pubmed.ncbi.nlm.nih.gov/31928404/ Adjuvant Therapy for Breast Cancer https://emedicine.medscape.com/article/1946040-overview Tumor Infiltrating Lymphocytes (TILs) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications From Pathologist's Perspective https://pubmed.ncbi.nlm.nih.gov/37760449/
--------
17:20
--------
17:20
S1 Episode 5: Shared Decision-Making in Sequencing ADCs for HER2-Low Breast Cancer
Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001337. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions https://pubmed.ncbi.nlm.nih.gov/37762027/ Pathological Identification of HER2-Low Breast Cancer: Tips, Tricks, and Troubleshooting for the Optimal Test https://pubmed.ncbi.nlm.nih.gov/37077201/ Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/ Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) https://pubmed.ncbi.nlm.nih.gov/32954927/ Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles https://pubmed.ncbi.nlm.nih.gov/38132377/ Subtypes of Breast Cancer https://www.ncbi.nlm.nih.gov/books/NBK583808/ Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/ Trastuzumab Deruxtecan in Metastatic Breast Cancer With Variable HER2 Expression: The Phase 2 DAISY Trial https://pubmed.ncbi.nlm.nih.gov/37488289/ Decoding TROP2 in Breast Cancer: Significance, Clinical Implications, and Therapeutic Advancements https://pubmed.ncbi.nlm.nih.gov/37954074/ TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (TRADE DXd) https://clinicaltrials.gov/study/NCT06533826
--------
24:27
--------
24:27
S1 Episode 4: Managing Central Nervous System Metastasis in Patients With HER2-Positive Breast Cancer
Drs Kathy Miller and Nancy U. Lin discuss central nervous system involvement in HER2-positive breast cancer, including the biology and management of patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/34208287/ Adjuvant Trastuzumab Emtansine in HER2-Positive Breast Cancer Patients With HER2-Negative Residual Invasive Disease in KATHERINE https://pubmed.ncbi.nlm.nih.gov/36117201/ Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions https://pubmed.ncbi.nlm.nih.gov/38241599/ Anti-Angiogenic Therapy: Current Challenges and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/33916438/ ALK-Positive Lung Cancer: A Moving Target https://pubmed.ncbi.nlm.nih.gov/36797503/ Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift https://pubmed.ncbi.nlm.nih.gov/35326665/ Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies https://pubmed.ncbi.nlm.nih.gov/38471052/ Stereotactic Radiosurgery and Local Control of Brain Metastases From Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36433878/ Multi-institutional Validation of Brain Metastasis Velocity, a Recently Defined Predictor of Outcomes Following Stereotactic Radiosurgery https://pubmed.ncbi.nlm.nih.gov/31526671/ Hippocampal Avoidance Whole Brain Radiotherapy in Brain Metastasis Using Volumetric Modulated Arc Therapy: Experience From a Regional Cancer Centre of Eastern India https://pubmed.ncbi.nlm.nih.gov/37795235/ Leptomeningeal Metastases https://emedicine.medscape.com/article/1156338-overview Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis https://pubmed.ncbi.nlm.nih.gov/35802849/ A Phase I/II Study of Intrathecal Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive (HER2-Positive) Cancer With Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics https://pubmed.ncbi.nlm.nih.gov/35948282/ Tucatinib-Trastuzumab-Capecitabine for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: TBCRC049 Phase 2 Study Results https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2018 Radiological Response of Leptomeningeal Metastases According to Revised RANO Criteria Is Associated With Overall Survival in Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/37243480/
Sobre Medscape InDiscussion: Breast Cancer and HER2
Listen to Medscape InDiscussion: Breast Cancer and HER2, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001124. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Brasil